Health - Malaria
First Malaria Vaccine Approved by W.H.O. By Apoorva Mandavilli
THE WORLD HEALTH ORGANIZATION on Wednesday, October 6th, endorsed the first ever vaccine to prevent malaria, debuting a tool that could save the lives of tens of thousands of children in Africa each year. Malaria is among the oldest known and deadliest of infectious diseases. It kills about half a million people each year, nearly all of them in sub-Saharan Africa — among them 260,000 children under age 5. The new vaccine, made by GlaxoSmithKline, rouses a child’s immune system to thwart Plasmodium falciparum, the deadliest of five malaria pathogens and the most prevalent in Africa. The vaccine is not just a first for malaria — it is the first developed for any parasitic disease. In clinical trials, the vaccine had an efficacy of about 50% against severe malaria in the first year, but dropped close to zero by the fourth year. And the trials did not measure the vaccine’s impact on preventing deaths, which has led some experts to question whether it is a worthwhile investment in countries with countless other intractable problems. But severe malaria accounts for up to half of malaria deaths and is considered “a reliable proximal indicator of mortality,” said Dr. Mary Hamel, who leads the W.H.O.’s malaria vaccine implementation program. “I do expect we will see that impact.” A modeling study last year estimated that if the vaccine were rolled out to countries with the highest incidence of malaria, it could prevent 5.4 million cases and 23,000 deaths in children younger than age 5 each year. And a recent trial of the vaccine in combination with preventive drugs given to children during hightransmission seasons found that the dual approach was much more effective at preventing severe disease, hospitalization and death than either method alone. To have a malaria vaccine that is safe, moderately effective and ready for distribution is “a historical 52
November-December 2021
event,” said Dr. Pedro Alonso, director of the W.H.O.’s global malaria program. Parasites are much more complex than viruses or bacteria, and the quest for a malaria vaccine has been underway for a hundred years, he added: “It’s a huge jump from the science perspective to have a firstgeneration vaccine against a human ▲▲ A baby receive vaccine Mosquirix, i parasite.” The malaria parasite is a particularly Ghana, in 2019. Cre insidious enemy, because it can strike Aldehuela/Agence F — Getty Images the same person over and over. In many parts of sub-Saharan Africa, even those where most people sleep under insecticide-treated bed nets, children have on average six malaria episodes a year. Even when the disease is not fatal, the repeated assault on their bodies can leave them weak and vulnerable to other pathogens, permanently altering the immune system. Malaria research is littered with vaccine candidates that never made it past clinical trials. Bed nets, the most widespread preventive measure, cut malaria deaths in children under age 5 by only about 20%. Against that backdrop, the new vaccine, even with modest efficacy, is the best new development in the fight against the disease in decades, some experts said. “Progress against malaria has really stalled over the last five or six years, particularly in some of the hardest hit countries in the world,” said Ashley Birkett, who heads malaria programs at PATH, a nonprofit organization focused on global health. With the new vaccine, “there’s potential for very, very significant impact there,” Dr. Birkett said. Called Mosquirix, the new vaccine is given in DAWN
www.africabusinessassociation.org
